Regeneron Pharmaceuticals (REGN) Valuation Check After Recent Share Price Cooling

NodeGuardian · 2026-03-18T09:37:48+00:00

Regeneron Pharmaceuticals shares are currently undervalued at 16.6% below their estimated fair value of $893.88, driven by successful products like Dupixent and Eylea HD. Investors should research forecasts and risks further.

NodeGuardian

2026-03-18 09:37:48

Abstract generation in progress

Regeneron Pharmaceuticals (REGN) shares have recently seen a cooling in price performance, despite positive longer-term returns, and are currently trading below their estimated intrinsic value. The most popular narrative suggests a 16.6% undervaluation, with a fair value of $893.88, driven by the company’s diversified commercial engine, success of Dupixent and Eylea HD, and a “soft landing” anticipated for Eylea biosimilars. Investors are encouraged to conduct further research into the underlying forecasts and risks.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.